Table 5 Factors associated with pathological Gleason score ≥ 8 in entire cohort and each risk group

OR

95%CI

p-value

PSAD >0.345 vs ≤0.345 ng/ml/cc

1.510

0.697–3.280

0.296

% positive cores >21.4 vs ≤21.4%

1.350

0.739–2.450

0.331

% dominant side >37.5 vs ≤37.5%

1.440

0.788–2.620

0.237

% cancer extent >55.6 vs ≤55.6%

1.460

0.789–2.710

0.228

NCCN risk high vs intermediate

5.650

2.950–10.80

<0.001

OR

95%CI

p-value

PSAD >0.190 vs ≤0.190 ng/ml/cc

1.860

0.668–5.160

0.236

% positive cores >21.4 vs ≤21.4%

0.733

0.244–2.200

0.580

% dominant side >36.4 vs ≤36.4%

0.696

0.243–1.990

0.500

% cancer extent >57.1 vs ≤57.1%

1.660

0.590–4.650

0.338

OR

95%CI

p-value

PSAD >0.345 vs ≤0.345 ng/ml/cc

1.100

0.412-2.930

0.849

% positive cores >35.0 vs ≤35.0%

1.260

0.483–3.310

0.632

% dominant side >40.0 vs ≤40.0%

2.100

0.912–4.830

0.081

% cancer extent >55.6 vs ≤55.6%

1.020

0.437–2.390

0.959